{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T20:33:29Z","timestamp":1783110809601,"version":"3.54.6"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.pcad.2022.05.008","type":"journal-article","created":{"date-parts":[[2022,6,5]],"date-time":"2022-06-05T17:08:09Z","timestamp":1654448889000},"page":"4-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Antithrombotic treatment for valve prostheses: Which drug, which dose, and when?"],"prefix":"10.1016","volume":"72","author":[{"given":"Elisabetta","family":"Ricottini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annunziata","family":"Nusca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Paolo","family":"Ussia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Grigioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2022.05.008_bb0005","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/hrt.2010.205096","article-title":"Valvular heart disease: the next cardiac epidemic","volume":"97","author":"d\u2019Arcy","year":"2011","journal-title":"Heart."},{"key":"10.1016\/j.pcad.2022.05.008_bb0010","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0140-6736(06)69208-8","article-title":"Burden of valvular heart diseases: a population-based study","volume":"368","author":"Nkomo","year":"2006","journal-title":"Lancet."},{"key":"10.1016\/j.pcad.2022.05.008_bb0015","first-page":"325","article-title":"Biological heart valves","volume":"36","author":"Hoerstrup","year":"2015","journal-title":"Eur Heart J"},{"issue":"43","key":"10.1016\/j.pcad.2022.05.008_bb0020","first-page":"561","article-title":"ESC\/EACTS guidelines for the management of valvular heart disease","volume":"2022","author":"Vahanian","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2022.05.008_bb0025","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jacc.2020.11.035","article-title":"2020 ACC\/AHA gGuideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"77","author":"Otto","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2022.05.008_bb0030","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1093\/europace\/eux240","volume":"19","author":"Lip","year":"2017","journal-title":"Europace."},{"key":"10.1016\/j.pcad.2022.05.008_bb0035","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJMoa1613792","article-title":"Mechanical or biologic protheses for aortic and mitral replacement","volume":"377","author":"Goldstone","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.pcad.2022.05.008_bb0040","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/01.CIR.89.2.635","article-title":"Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses","volume":"89","author":"Cannegieter","year":"1994","journal-title":"Circulation."},{"key":"10.1016\/j.pcad.2022.05.008_bb0045","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJM199507063330103","article-title":"Optimal oral anticoagulant therapy in patients with mechanical heart valves","volume":"333","author":"Cannegieter","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2022.05.008_bb0050","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1093\/eurheartj\/ehz372","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk","volume":"40","author":"Urban","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2022.05.008_bb0055","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1016\/j.jacc.2016.10.005","article-title":"Anticoagulant-related bleeding and mortality","volume":"68","author":"Connolly","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2022.05.008_bb0060","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1016\/j.jacc.2016.09.944","article-title":"Causes of death in anticoagulated patients with atrial fibrillation","volume":"68","author":"G\u00f3mez-Outes","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2022.05.008_bb0065","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1111\/jocs.15034","article-title":"Anticoagulation and antiplatelet therapy in patients with prosthetic heart valves","volume":"35","author":"Aikins","year":"2020","journal-title":"J Card Surg"},{"issue":"6","key":"10.1016\/j.pcad.2022.05.008_bb0070","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.thromres.2015.10.044","article-title":"INR variability and outcomes in patients with mechanical heart valve prosthesis","volume":"136","author":"Labaf","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.pcad.2022.05.008_bb0075","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/bjh.16528","article-title":"Determinants of low-quality warfarin anticoagulation in patients with mechanical prosthetic heart valves. The nationwide PLECTRUM study","volume":"190","author":"Pastori","year":"2020","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.pcad.2022.05.008_bb0080","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.jtcvs.2014.01.004","article-title":"Reduced anticoagulation after mechanical aortic valve replacement: interim results from the prospective randomized on-X valve anticoagulation clinical trial randomized Food and Drug Administration investigational device exemption trial","volume":"147","author":"Puskas","year":"2014","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.pcad.2022.05.008_bb0085","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/CRD.0000000000000105","article-title":"On-X valve: the next generation aortic valve","volume":"25","author":"Chaudary","year":"2017","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.pcad.2022.05.008_bb0090","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1016\/j.jacc.2018.03.535","article-title":"Anticoagulation and antiplatelet strategies after on-X mechanical aortic valve replacement","volume":"71","author":"Puskas","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2022.05.008_bb0095","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/1076029607302544","volume":"13","author":"Pengo","year":"2007","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.pcad.2022.05.008_bb0100","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ahj.2010.05.005","article-title":"LOWERing the INtensity of oral anticoaGulant Therapy in patients with bileaflet mechanical aortic valve replacement: results from the \u201cLOWERING-IT\u201d Trial","volume":"160","author":"Torella","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.pcad.2022.05.008_bb0105","doi-asserted-by":"crossref","first-page":"8405","DOI":"10.1038\/s41598-018-26528-9","article-title":"Low-dose anticoagulation after isolated mechanical aortic valve replacement with Liva Nova Bicarbon prosthesis: a post hoc analysis of LOWERING-IT trial","volume":"8","author":"Torella","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.pcad.2022.05.008_bb0110","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1093\/eurheartj\/ehm391","article-title":"Low-dose oral anticoagulation in patients with mechanical heart valve prostheses: final report from the early self-management anticoagulation trial II","volume":"28","author":"Koertke","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2022.05.008_bb0115","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/eurheartj\/ehu330","article-title":"Telemedicine-guided, very low-dose international normalized ratio self-control in patients with mechanical heart valve implants","volume":"36","author":"Koertke","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2022.05.008_bb0120","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/icvts\/ivx028","article-title":"Low target-INR anticoagulation is safe in selected aortic valve patients with the Medtronic Open Pivot mechanical prosthesis: longterm results of a propensity-matched comparison with standard anticoagulation","volume":"24","author":"Bove","year":"2017","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"10.1016\/j.pcad.2022.05.008_bb0125","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1055\/s-0038-1637755","article-title":"International normalized ratio targets for left-sided mechanical valve replacement","volume":"118","author":"Gupta","year":"2018","journal-title":"Thromb Haemost"},{"issue":"8","key":"10.1016\/j.pcad.2022.05.008_bb0130","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1056\/NEJM199308193290802","article-title":"A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement","volume":"329","author":"Turpie","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2022.05.008_bb0135","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0735-1097(99)00598-7","article-title":"Early and long-term (one-year) effects of the association of aspirin and oral anticoagulant on thrombi and morbidity after replacement of the mitral valve with the St. Jude Medical prosthesis","volume":"35","author":"Laffort","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2022.05.008_bb0140","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0002-8703(77)80351-7","article-title":"Prevention of arterial thromboembolism with acetylsalicylic acid","volume":"94","author":"Dale","year":"1977","journal-title":"Am Heart J"},{"key":"10.1016\/j.pcad.2022.05.008_bb0145","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/0002-9149(83)90673-2","article-title":"Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole","volume":"51","author":"Chesebro","year":"1983","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2022.05.008_bb0150","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1016\/j.thromres.2011.07.006","article-title":"Anticoagulation therapy with combined low dose aspirin and warfarin following mechanical heart valve replacement","volume":"128","author":"Dong","year":"2011","journal-title":"Thromb Res"},{"key":"10.1016\/j.pcad.2022.05.008_bb0155","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/S0022-5223(97)70264-2","article-title":"Low-intensity oral anticoagulation plus low-dose aspirin versus high-intensity oral anticoagulation alone: a randomized trial in patients with mechanical prosthetic heart valves","volume":"113","author":"Meschengieser","year":"1997","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"6","key":"10.1016\/j.pcad.2022.05.008_bb0160","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1007\/s11596-014-1371-4","article-title":"Combined low-dose aspirin and warfarin anticoagulant therapy of postoperative atrial fibrillation following mechanical heart valve replacement","volume":"34","author":"Wang","year":"2014","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"key":"10.1016\/j.pcad.2022.05.008_bb0165","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/j.thromres.2010.06.011","article-title":"In vitro comparison of dabigatran, unfractionated heparin, and low-molecular-weight heparin in preventing thrombus formation on mechanical heart valves","volume":"126","author":"Maegdefessel","year":"2010","journal-title":"Thromb Res"},{"key":"10.1016\/j.pcad.2022.05.008_bb0170","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3109\/08941939.2011.616256","article-title":"Dabigatran versus warfarin after mechanical mitral valve replacement in the swine model","volume":"25","author":"Schomburg","year":"2012","journal-title":"J Invest Surg"},{"issue":"13","key":"10.1016\/j.pcad.2022.05.008_bb0175","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Van de Werf F fort he RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2022.05.008_bb0180","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1161\/CIRCULATIONAHA.118.035612","article-title":"Non\u2013vitamin K antagonist oral anticoagulants for mechanical heart valves","volume":"138","author":"Aimo","year":"2018","journal-title":"Circulation."},{"key":"10.1016\/j.pcad.2022.05.008_bb0185","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/ejcts\/ezt545","article-title":"Effectiveness of rivaroxaban for thromboprophylaxis of prosthetic heart valves in a porcine heterotopic valve model","volume":"45","author":"Greiten","year":"2014","journal-title":"Eur J Cardiothorac Surg"},{"issue":"5","key":"10.1016\/j.pcad.2022.05.008_bb0190","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1161\/ATVBAHA.116.308649","article-title":"Apixaban versus warfarin for mechanical heart valve thromboprophylaxis in a swine aortic heterotopic valve model","volume":"37","author":"Lester","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pcad.2022.05.008_bb0195","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.amjcard.2018.06.015","article-title":"Usefulness and safety of rivaroxaban in patients following isolated mitral valve replacement with a mechanical prosthesis","volume":"122","author":"Dur\u00e3es","year":"2018","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2022.05.008_bb0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2019.12.005","article-title":"Rivaroxaban in patients with mechanical heart valves: A pilot study","volume":"186","author":"Roost","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.pcad.2022.05.008_bb0205","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ahj.2020.06.014","article-title":"Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve","volume":"227","author":"Jawitz","year":"2020","journal-title":"Am Heart J"},{"key":"10.1016\/j.pcad.2022.05.008_bb0210","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1161\/CIRCULATIONAHA.105.575571","article-title":"Low-molecular-weight heparin as a bridging anticoagulant early after mechanical heart valve replacement","volume":"113","author":"Meurin","year":"2006","journal-title":"Circulation."},{"key":"10.1016\/j.pcad.2022.05.008_bb0215","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1161\/01.CIR.101.10.1083","article-title":"Low molecular weight heparin after mechanical heart valve replacement","volume":"101","author":"Montalescot","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2022.05.008_bb0220","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.amjcard.2003.09.054","article-title":"Comparison of efficacy, safety, and cost of low-molecular-weight heparin with continuous-infusion unfractionated heparin for initiation of anticoagulation after mechanical prosthetic valve implantation","volume":"93","author":"Fanikos","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2022.05.008_bb0225","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1111\/jth.13047","article-title":"Early postoperative bridging anticoagulation after mechanical heart valve replacement: a systematic review and meta-analysis","volume":"13","author":"Passaglia","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.pcad.2022.05.008_bb0230","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s11886-020-01390-2","article-title":"Bridging anticoagulation with mechanical heart valves: current guidelines and clinical decisions","volume":"22","author":"Ali","year":"2020","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.pcad.2022.05.008_bb0235","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1056\/NEJMoa1501035","article-title":"Perioperative bridging anticoagulation in patients with atrial fibrillation","volume":"373","author":"Douketis","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2022.05.008_bb0240","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1161\/CIRCULATIONAHA.117.029479","article-title":"The fluid mechanics of transcatheter heart valve leaflet thrombosis in the neosinus","volume":"136","author":"MidhaPA","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2022.05.008_bb0245","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/HCO.0000000000000828","article-title":"Antithrombotic therapy after transcatheter aortic valve replacement: current perspective","volume":"36","author":"Eckstein","year":"2021","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.pcad.2022.05.008_bb0250","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/0735-1097(94)00563-6","article-title":"High risk of thromboemboli early after bioprosthetic cardiac valve replacement","volume":"25","author":"Heras","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2022.05.008_bb0255","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1001\/jama.2012.54506","article-title":"Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding","volume":"308","author":"Merie","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2022.05.008_bb0260","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.jacc.2007.10.058","article-title":"Thromboembolic complications after surgical correction of mitral regurgitation incidence, predictors, and clinical implications","volume":"51","author":"Russo","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2022.05.008_bb0265","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jtcvs.2004.11.028","article-title":"Is early anticoagulation with warfarin necessary after bioprosthetic aortic valve replacement?","volume":"129","author":"Sundt","year":"2005","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.pcad.2022.05.008_bb0270","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.jtcvs.2009.10.064","article-title":"Is early antithrombotic therapy necessary in patients with bioprosthetic aortic valves in normal sinus rhythm?","volume":"139","author":"ElBardissi","year":"2010","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.pcad.2022.05.008_bb0275","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.jacc.2019.06.058","article-title":"Anticoagulation after surgical or transcatheter bioprosthetic aortic valve replacement","volume":"74","author":"Chakravarty","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2022.05.008_bb0280","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.ijcard.2012.11.056","article-title":"Low-dose acetyl salicylic acid versus oral anticoagulation after bioprosthetic aortic valve replacement. Final report of the ACTION registry","volume":"168","author":"Colli","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pcad.2022.05.008_bb0285","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/ejcts\/ezv254","article-title":"Antithrombotic strategy after bioprosthetic aortic valve replacement in patients in sinus rhythm: evaluation of guideline implementation","volume":"49","author":"van der Wall","year":"2016","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.pcad.2022.05.008_bb0290","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.thromres.2016.11.021","article-title":"Antithrombotic therapy after bioprosthetic aortic valve implantation: warfarin versus aspirin, a randomized controlled trial","volume":"150","author":"Rafiq","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.pcad.2022.05.008_bb0295","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jacc.2012.05.029","article-title":"Early anticoagulation of bioprosthetic aortic valves in older patients: results from the Society of Thoracic Surgeons Adult Cardiac Surgery National Database","volume":"60","author":"Brennan","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2022.05.008_bb0300","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/jocs.15314","article-title":"Risks and benefit of concurrent treatment with antiplatelet and anticoagulation therapy in post-op bioprosthetic aortic valve replacement patients","volume":"36","author":"Yaghi","year":"2021","journal-title":"J Card Surg"},{"key":"10.1016\/j.pcad.2022.05.008_bb0305","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.athoracsur.2018.10.016","article-title":"Antithrombotic stretegies after bioprosthetic valve replacement: a systematic review","volume":"107","author":"Papk","year":"2019","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.pcad.2022.05.008_bb0310","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1136\/heartjnl-2019-315453","article-title":"Comparison of warfarin versus antiplatelet therapy after surgical bioprosthetic aortic valve replacement","volume":"106","author":"Christersson","year":"2020","journal-title":"Heart"},{"issue":"21","key":"10.1016\/j.pcad.2022.05.008_bb0315","volume":"S0022-5223","author":"Shim","year":"2021","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.pcad.2022.05.008_bb0320","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/clc.23178","article-title":"Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: insights from the ARISTOTLE trial","volume":"42","author":"Guimar\u00e3es","year":"2019","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.pcad.2022.05.008_bb0325","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1161\/CIRCULATIONAHA.116.026714","article-title":"Edoxaban for the prevention of thromboembolism in patients with atrial fibrillation and bioprosthetic valves","volume":"135","author":"Carnicelli","year":"2017","journal-title":"Circulation."},{"key":"10.1016\/j.pcad.2022.05.008_bb0330","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1016\/j.clinthera.2019.10.008","article-title":"Clinical benefit of direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and bioprosthetic heart valves","volume":"41","author":"Russo","year":"2019","journal-title":"Clin Ther"},{"key":"10.1016\/j.pcad.2022.05.008_bb0335","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.amjcard.2021.01.016","article-title":"Comparison of direct oral anticoagulants versus warfarin in patients with atrial fibrillation and bioprosthetic heart valves","volume":"146","author":"Duan","year":"2021","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2022.05.008_bb0340","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s40261-020-00939-x","article-title":"Comparison of the efficacy and safety of direct oral anticoagulants and warfarin after bioprosthetic valve replacements","volume":"40","author":"Pasciolla","year":"2020","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.pcad.2022.05.008_bb0345","article-title":"New oral anticoagulants versus warfarin in atrial fibrillation after early post-operative period in patients with bioprosthetic aortic valve","author":"Mannacio","year":"2021","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.pcad.2022.05.008_bb0350","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40268-016-0124-1","article-title":"Dabigatran versus warfarin after bioprosthesis valve replacement for the management of atrial fibrillation postoperatively: DAWA pilot study","volume":"16","author":"Dur\u00e3es","year":"2016","journal-title":"Drugs R D"},{"key":"10.1016\/j.pcad.2022.05.008_bb0355","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa2029603","article-title":"Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve","volume":"383","author":"Guimar\u00e3es","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2022.05.008_bb0360","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1016\/j.jacc.2020.04.043","article-title":"Subclinical leaflet thrombosis in transcatheter and surgical bioprosthetic valves: PARTNER 3 cardiac computed tomography substudy","volume":"75","author":"Makkar","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2022.05.008_bb0365","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.amjcard.2011.07.049","article-title":"Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation","volume":"108","author":"Ussia","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2022.05.008_bb0370","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.jcin.2017.04.014","article-title":"Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve","volume":"10","author":"Rod\u00e9s-Cabau","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2022.05.008_bb0375","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1253\/circj.CJ-16-0903","article-title":"Clinical outcomes and bioprosthetic valve function after transcatheter aortic valve implantation under dual antiplatelet therapy vs. aspirin alone","volume":"81","author":"Ichibori","year":"2017","journal-title":"Circ J"},{"key":"10.1016\/j.pcad.2022.05.008_bb0380","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ahj.2018.06.006","article-title":"Variation in post-TAVR antiplatelet therapy utilization and associated outcomes: insights from the STS\/ACC TVT registry","volume":"204","author":"Sherwood","year":"2018","journal-title":"Am Heart J"},{"key":"10.1016\/j.pcad.2022.05.008_bb0385","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.amjcard.2018.04.006","article-title":"Meta-analysis comparing single versus dual antiplatelet therapy following transcatheter aortic valve implantation","volume":"122","author":"Maes","year":"2018","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2022.05.008_bb0390","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1056\/NEJMoa2017815","article-title":"Aspirin with or without clopidogrel after transcatheter aortic-valve implantation","volume":"383","author":"Brouwer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2022.05.008_bb0395","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1093\/eurheartj\/ehaa800","article-title":"Aspirin monotherapy vs. DAPT after TAVI: is less more? Comment on the POPular TAVI Trial","volume":"41","author":"Galiuto","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2022.05.008_bb0400","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jacc.2018.08.1045","article-title":"Long-term mortality and early valve dysfunction according to anticoagulation use: the FRANCE TAVI Registry","volume":"73","author":"Overtchouk","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2022.05.008_bb0405","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa1911425","article-title":"A controlled trial of rivaroxaban after transcatheter aortic-valve replacement","volume":"382","author":"Dangas","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2022.05.008_bb0410","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1911426","article-title":"Reduced leaflet motion after transcatheter aortic-valve replacement","volume":"382","author":"De Backer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2022.05.008_bb0415","series-title":"Presented by Dr. Jean-Philippe Collet at the American College of Cardiology Virtual Annual Scientific Session (ACC 2021), May 15","year":"2021"},{"key":"10.1016\/j.pcad.2022.05.008_bb0420","series-title":"Presented by Dr. Gilles Montalescot at the American College of Cardiology Virtual Annual Scientific Session (ACC 2021), May 15","year":"2021"},{"key":"10.1016\/j.pcad.2022.05.008_bb0425","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa1915152","article-title":"Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation","volume":"382","author":"Nijenhuis","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2022.05.008_bb0430","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.jcin.2019.03.003","article-title":"Oral anticoagulant type and outcomes after transcatheter aortic valve replacement","volume":"12","author":"Jochheim","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2022.05.008_bb0435","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.jacc.2019.07.018","article-title":"Should bioprosthetic aortic valves be routinely anticoagulated? Insights from PARTNER and beyond","volume":"74","author":"Pibarot","year":"2019","journal-title":"J Am Coll Cardiol"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062022000597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062022000597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:20:33Z","timestamp":1758500433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062022000597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":87,"alternative-id":["S0033062022000597"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2022.05.008","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antithrombotic treatment for valve prostheses: Which drug, which dose, and when?","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2022.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}